Feb 15 2023 13 mins
This episode deep-dives into immune responses of hematological patients, with a special focus on the most high-risk patients within this group. What do we know with regards to antibody responses in these patients? How is it measured and interpreted? Where are the gaps in terms of interpretation and clinical decision making based on antibody responses in CLL patients/hematological patients? What do we know about T-cell responses in these patients and how can this be used in clinical decision making? Which guidelines are in place? What do we know of the potential T-cell dysfunction in CLL patients? Finally, what are the unmet needs with regards to management of COVID-19 in these patients?
References: 1. Williamson EJ et al. Nature. 2020;584(7821):430-436. 2. Langerbeins P et al, Blood vol. 140,3 (2022): 236-252. 3. Obeid M et al. JAMA oncology vol. 8,5 (2022): e220446. 4. Benning L et al. Clinical journal of the American Society of Nephrology, vol. 17,1 (2022): 98-106. 5. Jiménez M et al. Blood advances vol. 6,3 (2022): 774-784. 6. Mellinghoff SC et al. Haematologica vol. 107,10 2480-2484. 1 Oct. 2022. 7. Wherry EJ et al, Science vol. 377,6608 (2022): 821-822.
XN-1390-02-23-ONC